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Cotranslational insertion of type I collagen chains into the lumen of the endoplasmic reticulum (ER) and
their subsequent folding into a heterotrimeric helix is a complex process which requires coordinated action of
the translation machinery, components of translocons, molecular chaperones, and modifying enzymes. Here we
describe a role for the protein TRAM2 in collagen type I expression in hepatic stellate cells (HSCs) and
fibroblasts. Activated HSCs are collagen-producing cells in the fibrotic liver. Quiescent HSCs produce trace
amounts of type I collagen, while upon activation collagen synthesis increases 50- to 70-fold. Likewise,
expression of TRAM2 dramatically increases in activated HSCs. TRAM2 shares 53% amino acid identity with
the protein TRAM, which is a component of the translocon. However, TRAM2 has a C terminus with only a 15%
identity. The C-terminal part of TRAM2 interacts with the Ca2 pump of the ER, SERCA2b, as demonstrated
in a Saccharomyces cerevisiae two-hybrid screen and by immunoprecipitations in human cells. TRAM2 also
coprecipitates with anticollagen antibody, suggesting that these two proteins interact. Deletion of the C-
terminal part of TRAM2 inhibits type I collagen synthesis during activation of HSCs. The pharmacological
inhibitor of SERCA2b, thapsigargin, has a similar effect. Depletion of ER Ca2 with thapsigargin results in
inhibition of triple helical collagen folding and increased intracellular degradation. We propose that TRAM2,
as a part of the translocon, is required for the biosynthesis of type I collagen by coupling the activity of
SERCA2b with the activity of the translocon. This coupling may increase the local Ca2 concentration at the
site of collagen synthesis, and a high Ca2 concentration may be necessary for the function of molecular
chaperones involved in collagen folding.
Cirrhosis is characterized by the accumulation of extracellu-
lar matrix proteins in the liver, including type I collagen (3, 43).
Hepatic stellate cells (HSCs, also named Ito cells, lipocytes, or
fat-storing cells) are the major cell type responsible for colla-
gen synthesis in the cirrhotic liver (16, 33). In a normal liver,
quiescent HSCs store vitamin A (26) but express only trace
amounts of type I collagen (46). Upon a fibrogenic stimulus,
HSCs become activated, a process in which they lose retinoid
droplets, proliferate, change morphologically into myofibro-
blasts, and increase their synthesis of extracellular matrix pro-
teins (19, 30). Culturing quiescent HSCs on plastic causes
activation similar to that seen in liver fibrosis in vivo, including
the accumulation of COL1A1 mRNA and synthesis of type I
procollagen (20, 30). COL1A1 mRNA increases 50- to 70-fold
in activated HSCs compared to quiescent HSCs. Procollagen
1(I) [pro-1(I)] is undetectable by Western blotting in quies-
cent HSCs, and its level starts to increase after 4 days in culture
(unpublished result). After translation initiation, individual
pro- chains are cotranslationally inserted into the endoplas-
mic reticulum (ER). Insertion is driven by the ribosome en-
gaged in translation elongation and attached to the translocon.
The translocon is a gated channel through the ER membrane
and is composed of Sec61, Sec61, Sec61, and the translo-
cation-associated membrane protein (TRAM). Proteins asso-
ciated with the translocon that are not integral components
include signal peptidase, oligosaccharyltransferase, BiP, ribo-
some receptors, and the signal recognition particle receptor
(28). During cotranslational insertion, pro- chains undergo
hydroxylation of prolyl and lysyl residues, glycosylation of hy-
droxylysyl residues, attachment of N-linked oligosaccharide in
the C-terminal propeptide, and intrachain disulfide bond for-
mation. Following interchain disulfide cross-linking, two pro-
1(I) chains and one pro-2(I) chain are folded into a triple
helix (29, 31, 54). There is evidence that procollagen chains
initiate assembly into the trimer while they are still associated
with ribosomes on the membrane of the ER (5, 8, 53). Modi-
fications of individual chains and their assembly into a triple
helix seem to be in kinetic equilibrium, because mutations
which affect the rate of assembly result in hypermodifications
of the chains (4, 18). The assembly process is facilitated by the
actions of several molecular chaperones. Protein disulfide
isomerase (PDI) is a subunit of prolyl hydroxylase that associ-
ates as a monomer with nascent pro- chains before incorpo-
ration into the triple helix (7, 56). It has been postulated that
PDI prevents misfolding of individual chains until they assem-
ble into the trimer (6). Another molecular chaperone, BIP, has
been reported to bind misfolded chains and target them for
degradation (11). While PDI and BIP are ubiquitous chaper-
ones, HSP 47 is chaperone specific for various collagens (37).
HSP 47 seems to associate with prefolded procollagen triple
helices, preventing their aggregation and facilitating their ex-
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port into the Golgi complex (51, 52). HSP 47-deficient mice die
at embryonic day 11 with abnormalities in type I and type IV
collagen (36).
Molecular chaperones require Ca2 for function, and some
Ca2 storage proteins in the ER are chaperones themselves (2,
15, 34, 35). Depletion of ER Ca2 stores leads to the unfolded
protein response (UPR) of the cell (22, 41). The main Ca2
pump of HSCs and fibroblasts, which maintains a high Ca2
concentration within the ER, is sarcoplasmic-ER Ca2-
ATPase type 2b (Serca2b) (10, 27, 57). Serca2b is a ubiqui-
tously expressed transmembrane protein of the ER (9), but its
relationship with the translocon is unknown.
Here we report that TRAM2, a homolog of the TRAM
protein, is upregulated during activation of HSCs and that the
C-terminal part of TRAM2, which has a unique sequence,
interacts with Serca2b. TRAM2 without the C terminus or
treatment with pharmacological inhibitors of Serca2b inhibits
procollagen synthesis in HSCs. We suggest that during activa-
tion of HSCs TRAM2 is required for recruitment of Serca2b to
the translocon and that this couples procollagen synthesis and
a Ca2-dependent function of molecular chaperones. This
identifies TRAM2 as one of the key components required for
excessive collagen synthesis by activated HSCs.
MATERIALS AND METHODS
Constructs. Adenovirus for expression of full-size human TRAM2 was con-
structed by cloning the TRAM2 reverse transcriptase PCR (RT-PCR) product
made by reverse transcription of total RNA from activated human HSCs and
amplified with the primers 5-ATGGCTTTCCGCAGGAGGACG and 3-GGG
AGACTTGAGTTTCTTAGTCCG. The band of 1.1 kb was eluted from the gel
and reamplified with a new set of primers in which the 5 primer contained a
SmaI site and the 3 primer contained a SalI site. This second PCR product was
cloned into SmaI-SalI sites of pGEM3 (Promega). Sequencing of the full insert
confirmed the identity with the published sequence of the KIA0057 gene (Gen-
Bank accession number NM_012288) and no PCR errors. From this clone a
KpnI-SalI fragment was recloned into KpnI-XhoI sites of pCDNA3 vector (In-
vitrogen) for mammalian expression (H-TRAM2/pCDNA3). From the
H-TRAM2/pCDNA3 clone, the full-size TRAM2 was recloned into KpnI-XbaI
sites of pAdCMV-Track vector (TRAM2/Track). TRAM2 truncated by 66 amino
acids at the C terminus (TRAM2C/Track) was constructed by removing a
StuI-EcoRV fragment of TRAM2/Track and religating the vector. A double-
stranded oligonucleotide encoding two hemagglutinin (HA) tags was cloned in
frame at the N terminus into both TRAM2/Track and TRAM2C/Track clones.
Adenoviruses expressing these tagged proteins were constructed by recombina-
tion with pAD-Easy DNA in Escherichia coli and packaged into viral particles by
transfecting into 293 cells, as described previously (23). Control virus expressed
a short nonfunctional RNA instead of a protein (mutant molecular decoy) (44).
All viral vectors contained an additional independent transcription unit express-
ing green fluorescent protein (GFP), which served as a marker for viral infection.
Mouse TRAM2 was isolated by RT-PCR using total mouse liver RNA as the
source of RNA and single-step PCR amplification with the primers 5-ATGGC
TTTCCGTAGGAGGAC and 3-GGGAGACTTGAGTTTCTTAATC, fol-
lowed by cloning of a 1.1-kb PCR product into PCR2.1TOPO vector (Strat-
agene). From this clone, a PstI (blunt)-BamHI fragment encoding the C-terminal
145 amino acids of mouse TRAM2 was cloned into SmaI-BamHI sites of the
Saccharomyces cerevisiae two-hybrid vector pGBT-9 as bait. This bait was used to
screen an NIH 3T3 two-hybrid library (Clontech), using standard protocols for
two-hybrid screening (Clontech). Probes for an RNase protection assay have
been described before (46). Full-size human Serca2b cloned in the pCDNA3.1
vector was a kind gift of J. Lytton and was tagged with FLAG tag at the N
terminus by cloning a double-stranded oligonucleotide with the FLAG sequence
in frame at the 5 end of the coding sequence.
Cell culture and viral infections. Rat HSCs were isolated according to pub-
lished procedures (20). Total RNA was isolated either immediately after isola-
tion (quiescent HSCs) or after 7 days of culturing (activated HSCs) (13). For
expression studies, at day 2 after isolation the cells were infected at a multiplicity
of infection of 500 with adenoviruses expressing TRAM2, TRAM2C, or control
virus and cultured for an additional 5 days. Cellular proteins and media were
then collected and analyzed by Western blotting as described elsewhere (44, 47).
Human HSCs were isolated by perfusion of human liver explants with collage-
nase and pronase as described previously (42). Cells were cultured for the
indicated time periods, and total RNA was extracted. Fibroblasts were grown in
10% fetal calf serum and, where indicated, thapsigargin (Sigma) was added to
cell medium at 200 nM and calmidazolium Cl (Sigma) was added at 10 M.
MG132 (Sigma) was added at 100 M, lactacystin (Sigma) was added at 50 M,
and puromycin (Sigma) was used at 30 M for 2 h. In collagen secretion
experiments, the unhydrolyzable analog of ascorbic acid, AA-2P (Waco), was
added at 10 mM.
RNA and protein analysis. Rat TRAM2 expression was estimated by RT-PCR
of 100 ng of total RNA or 20 ng of poly(A) RNA, isolated from quiescent or
activated HSCs, using a TthRT-PCR kit (Perkin-Elmer) in the presence of
[32P]dCTP, as described previously (47). The primers were 5-TTGGCTTCGG
ATTGGCTCGG and 3-GCTGGGAGTGGATGAAACGC, which amplify a
145-nt product; 20 cycles were used for poly(A) RNA, and 30 cycles for total
RNA were used. The annealing and extension temperature was 55°C. Total RNA
from human HSCs was analyzed as above using the primers 5-TTGGCTTTG
GACTGGCTCGC and 3-GCTGGGAGTGGATGAAGCGC, which give a
143-nt product. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control
amplification was done as described before (47). PCR products were resolved on
6% denaturing gels, and the bands were excised, reamplified with the same
primers, and sequenced to confirm the identity of the products. TRAM and
Serca2b expression was analyzed by RT-PCR as for TRAM2 using the following
primers: for TRAM, 5-GAGCCATGAATTCGTGCTGC and 3-GCTGATTC
AGCAGCTTGTTC; for Serca2b, 5-CAAGGTGTATCGACAGGACAG and
3-CCACTGGTCAACTCTCAGAG. The annealing and extension temperature
was 50°C. RNase protection assays for collagen 1(I) mRNA were done as
described previously (45, 46).
Western blotting assays were done with 50 g of cellular proteins, as described
elsewhere (44, 47). When cellular medium was analyzed, equivalent amounts of
medium were used without prior concentration. The anticollagen antibody (600-
401-103; Rockland) has been characterized in previous papers (44, 47). Antical-
nexin antibody (C45520; BD Biosciences) and antifibronectin antibody (F14420;
BD Biosciences) were used as recommended by the manufacturer.
Immunoprecipitations. Expression vector (pCDNA3.1) encoding FLAG-
tagged human SERCA2b was transfected into human fibroblasts, and two stably
transfected cell lines were developed by selection with G418 for 2 months.
Expression was verified by Western blotting. Three p150 dishes of one cell line
were infected with adenoviruses expressing HA-tagged human TRAM2 and
HA-tagged human TRAM2C. Two days after infection, cell lysate was pre-
pared by homogenizing the cells in phosphate-buffered saline containing 0.5%
NP-40 and, after removal of nuclei by centrifugation, 1 mg of clear lysate was
incubated with either 10 l of anti-HA monoclonal antibody (HA-7; Sigma), 10
l of anti-FLAG monoclonal antibody (M2; Sigma), 10 l of antitubulin mono-
clonal antibody (MSA78G; Accurate), or 10 l of anticollagen polyclonal anti-
body (600-401-103; Rockland) for 1 h at 4°C. A 50-l volume of prewashed
protein A/G PLUS-agarose (Santa Cruz Biotechnology) was added to each tube,
and incubation continued for 1 h. After washing three times in lysis buffer,
samples were resuspended in sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis loading buffer and analyzed by Western blotting.
Measurement of intracellular Ca2. Cells cultured in 24-well plates were
loaded with the Ca2-sensitive dye Fluo-4 (10 M; Molecular Probes, Eugene,
Oreg.) for 20 min at 37°C. Cells were then rinsed twice with Dulbecco’s modified
Eagle’s medium and stimulated with dimethyl sulfoxide (DMSO) or thapsigar-
gin. Changes in intracellular Ca2 formation were estimated by measuring cell
fluorescence at 485/535 nm using a multiwell fluorescence scanner (CytoFluor
2300; Millipore, Bedford, Mass.).
RESULTS
TRAM2 is expressed in activated HSCs. To identify genes
differentially expressed in HSCs, we compared gene expression
profiles of activated HSCs and whole liver by using DNA
microarrays (unpublished data). One gene that was expressed
at a 3.3-fold higher level in HSCs than in whole liver was a
homolog of the TRAM protein. This protein has been se-
quenced as a part of human cDNA sequencing effort and
named KIAA 0057 (39); here we have named this protein
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TRAM2. Since extracellular matrix proteins, primarily colla-
gen type I, are secreted from HSCs and not from hepatocytes,
and since TRAM is an integral part of the translocon, we
surmised that TRAM2 may be involved in collagen secretion
from HSCs. Figure 1 shows the homology between human
TRAM and TRAM2 proteins, as well as with another member
of the TRAM superfamily with accession no. BC030831. Over-
all, there was 53% amino acid identity between TRAM and
TRAM2. TRAM has seven putative transmembrane regions
(Fig. 1), and the same topology can be predicted for TRAM2.
Transmembrane segments show the greatest similarity be-
tween the two proteins. The most divergent part is the C
terminus, which shows only 15% identity within a stretch of 40
amino acids (Fig. 1). This region of TRAM2 has no high
homology to any other protein, as assessed by a BLAST pro-
gram search (1). We cloned TRAM2 from the mouse, and it
showed 92% homology to the human ortholog, including the
C-terminal region (data not shown). There is yet another ho-
molog of human TRAM in GenBank: it is named “similar to
TRAM,” with accession number BC030831. The overall iden-
tity of this homolog to TRAM is 71% and its C-terminal
domain is 50% identical to TRAM, suggesting that these two
proteins are more related than TRAM and TRAM2 (Fig. 1).
Next, we validated expression of TRAM2 during culture
activation of rat HSCs by RT-PCR. Poly(A) RNA (Fig. 2A,
lanes 1 and 2) or total RNA (lanes 3 and 4) was extracted from
quiescent rat HSCs and from fully activated HSCs after 7 days
in culture. In both RNAs, there was about 20- to 30-fold
upregulation of TRAM2 mRNA in activated HSCs compared
to quiescent HSCs. Both PCR products that routinely resolved
on this gel represented TRAM2, as confirmed by excision of
the bands out of the gel and sequencing. They probably re-
FIG. 1. Sequence comparison between human TRAM, TRAM2, and BC030831. The amino acid sequences of TRAM (accession no. S30034),
TRAM2 (KIAA0057; accession no. D31762), and TRAM-like protein (accession no. BC030831) were aligned using the ClustalW program.
Identities are indicated as asterisks under the sequence, conserved residues in at least two proteins are shown as double dots, and conservative
substitutions are indicated by single dots. Putative transmembrane regions are overlined with dotted lines, and the most divergent C-terminal
domain is underlined with a solid line.
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sulted from denaturation of the double-stranded PCR product
in the denaturing gel with differential migration of the two
strands. So, total expression of TRAM2 was the sum of both
bands. Equal loading for poly(A) RNA was confirmed by
analyzing GAPDH mRNA (bottom panel). Using RT-PCR,
we also estimated expression of TRAM and Serca2b in quies-
cent and activated rat HSCs. The steady-state levels of TRAM
and Serca2b mRNAs did not change during activation of HSCs
(Fig. 2B). We also analyzed TRAM2 expression during culture
activation of human HSCs (Fig. 2C). No TRAM2 mRNA
could be detected in freshly isolated human HSCs (lane 1). At
day 2 in culture, while the cells were still in a quiescent state,
the mRNA was weakly expressed (lane 2); however, by days 12
and 17 (lanes 3 and 4) there was an approximately 20- to
50-fold increase in the steady-state level of TRAM2 mRNA
compared to that at day 2. Thus, the result with human HSCs
was similar to the result with rat HSCs. COL1A1 mRNA is
increased 50- to 70-fold during culture activation of HSCs (46),
and so expression levels of TRAM2 and COL1A1 mRNAs
were parallel.
TRAM2 interacts with the Ca2 pump of the ER Serca2b.
Based on the homology of TRAM2 and TRAM, especially due
to conservation of the transmembrane domains, it is likely that
TRAM2 also functions as a part of the translocon. To provide
insight into the function of the divergent C-terminal domain,
we performed a yeast two-hybrid screen to identify proteins
that interact with this domain of TRAM2 protein. As bait in
this screen, we used the cDNA which encodes the 145 C-
terminal amino acids of mouse TRAM2 and screened a library
of mouse fibroblast cDNA as representative of collagen-pro-
ducing cells. We screened 6 million clones and identified four
independent clones that specifically interacted with TRAM2.
They all encoded the C terminus of SERCA2b (57), another
ER transmembrane protein. To confirm that the two proteins
interact in human cells, we FLAG tagged human SERCA2b
and stably expressed the protein in human fibroblasts and then
infected these cells with adenovirus expressing HA-tagged hu-
man TRAM2 or TRAM2C. Expression of the tagged pro-
teins was determined by Western blotting (Fig. 3A, lane 1, B,
lanes 1 and 3, and C, lane 1). When the cellular proteins were
immunoprecipitated with anti-FLAG antibody and analyzed
with anti-HA antibody, a strong signal was observed (Fig. 3A,
lane 2). Antitubulin antibody gave only a weak background
signal (lane 3), suggesting that there was a specific interaction
between the two tagged proteins. When anticollagen antibody
was used for immunoprecipitation, HA-tagged TRAM2 pro-
tein was also pulled down (lane 4). Similar results were ob-
tained in the reverse experiment, when immunoprecipitation
was done with anti-HA antibody and the samples were ana-
lyzed with anti-FLAG antibody (Fig. 3C, lane 2). In this ex-
periment, however, anticollagen antibody did not pull down
Serca2b protein (lane 3), suggesting that there was no interac-
tion between procollagen 1(I) and Serca2b. When we ex-
pressed TRAM2C and immunoprecipitated with anti-FLAG
antibody, no TRAM2C protein was coimmunoprecipitated
with Serca2b (Fig. 3B, lane 2). This result suggests that the C
terminus of TRAM2 interacts specifically with Serca2b and is
consistent with yeast two-hybrid screening.
As additional controls for specificity of immunoprecipita-
tions, two experiments were performed. First, immunoprecipi-
tation was performed with anti-HA antibody and pulled down
material was analyzed with anticalnexin antibody. Calnexin is
an integral membrane protein of the ER. We could not detect
any calnexin signal after immunoprecipitation with anti-HA
antibody (Fig. 3D, lane 2), while this antibody strongly recog-
nized calnexin in the initial sample (lane 1). This suggests that
TRAM2 does not interact with calnexin. Second, we treated
the cells with puromycin for 2 h to inhibit protein synthesis.
During this time period there was no decrease in the steady-
state level of pro-1(I) or TRAM2, as analyzed by Western
blotting (Fig. 3E, lanes 1 and 2). Then, we performed immu-
noprecipitation with anticollagen antibody and analyzed the
amount of TRAM2 precipitated. As shown in Fig. 3E, lanes 3
and 4, there was less TRAM2 coprecipitated with procollagen
in puromycin-treated cells. This indicates that there is a trans-
FIG. 2. TRAM2 mRNA is induced in activated HSCs. (A) Expres-
sion in rat HSCs. Shown are results of RT-PCR analysis of RNA
isolated from fresh rat HSCs (Q) or from rat HSCs activated in culture
for 7 days (A). Twenty nanograms of poly(A) RNA (lanes 1 and 2) or
100 ng of total RNA (lanes 3 and 4) from two independent isolates of
HSCs was subjected to RT-PCR analysis with primers specific for rat
TRAM2. Poly(A) RNA samples were also analyzed with primers
specific to GAPDH (bottom panel). Migration of TRAM2-specific
bands is indicated. Both bands represent the same PCR product, as
confirmed by sequencing (see Results). (B) Expression of TRAM and
Serca2b in rat HSCs. RT-PCR was done as described for panel A, with
100 ng of total RNA extracted from quiescent (Q) and activated
(A) rat HSCs and with primers specific for TRAM (top panel),
Serca2b (middle panel), or GAPDH (bottom panel). Migration of
PCR products is indicated. GAPDH served as an internal control.
(C) Expression in human HSCs. A 100-ng aliquot of total RNA from
freshly isolated human HSCs (0, lane 1) or from human HSCs cultured
for 2 days (lane 2), 12 days (lane 3), or 17 days (lane 4) was analyzed
by RT-PCR with primers specific for human TRAM2. Identity of the
bands was confirmed by sequencing and is indicated on the right.
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lation-dependent interaction between pro-1(I) and TRAM2,
consistent with the interpretation that TRAM2 is involved in
cotranslational translocation of pro-(I) chains. From the
yeast two-hybrid screen and immunoprecipitation experiments,
we concluded that TRAM2 interacts with Serca2b and with
pro-1(I) chains.
TRAM2 with a C-terminal deletion inhibits collagen synthe-
sis by HSCs. The functional significance of the interaction
FIG. 3. TRAM2 and Serca2b proteins interact in human fibroblasts. (A) TRAM2 coprecipitates with Serca2b and with type I procollagen.
FLAG-tagged human Serca2b protein and HA-tagged human TRAM2 protein were expressed in human fibroblasts. Immunoprecipitation (IPP)
was done with 1 mg of cellular extract and using anti-FLAG antibody (lane 2; FL), antitubulin antibody (lane 3; TUB), or anticollagen antibody
(lane 4; COLL). Western blotting (WEST) was done with the precipitated material using anti-HA antibody (HA). Lane 1 is Western blotting only,
showing expression of HA-TRAM2 in 50 g of cellular extract. (B) TRAM2C does not interact with Serca2b. This experiment was done as
described for that in panel A, except that HA-tagged TRAM2C and FLAG-tagged Serca2b were coexpressed. Immunoprecipitation (IPP) was
done with anti-FLAG antibody (lane 2) or anti-HA antibody (lane 3), and Western blotting (WEST) was done with the precipitated material using
anti-HA antibody (lanes 2 and 3). Lane 1 is Western blotting only, showing expression of Serca2b in 50 g of cell extract. (C) Serca2b coprecipitates
with TRAM2, but not with procollagen. Immunoprecipitations were done with the same material as used for panel A, except that antibodies used
for IPP were anti-HA (lane 2, HA) or anticollagen (lane 3, COLL). Western blotting was done with anti-FLAG antibody (FLAG). Lane 1 is
Western blotting only, showing expression of FLAG-Serca2b in 50 g of cellular extract. (D) Calnexin does not coprecipitate with TRAM2.
Immunoprecipitations were done with the same material as used for panel A, except that the antibody used for IPP was anti-HA (lane 2, HA).
Western blotting was done with anticalnexin antibody (CLNX). Lane 1 is Western blotting only, showing expression of calnexin in 50 g of cellular
extract. (E) Interaction of TRAM2 and procollagen is translation dependent. Cells were incubated with puromycin () or without () for 2 h, and
extracts were analyzed by Western blotting for expression of procollagen and TRAM2 (lanes 1 and 2). The same samples were subjected to
immunoprecipitation with anticollagen antibody (COLL) (lanes 3 and 4). Western blotting was done with anti-HA antibody (HA). The signal from
coimmunoprecipitated TRAM2 protein in the absence () or presence () of puromycin is indicated as TRAM2.
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between TRAM2 and Serca2b was addressed by overexpress-
ing a C-terminal-truncated form of human TRAM2 during
activation of HSCs. We deleted 66 amino acids from the C
terminus of human TRAM2 (TRAM2C) and expressed the
protein at day 2 after isolation of rat HSCs, that is, before the
onset of increased collagen synthesis (20). The cells were then
cultured for an additional 5 days during which collagen syn-
thesis was activated, to assess if TRAM2C interfered with this
process. Full-size human TRAM2 served as one control in
these experiments to account for any effects of expression of
the human protein in rat cells. Adenovirus not expressing a
protein (control virus) served as another control for the effects
of viral load on HSCs. Cell morphology after expression of
TRAM2C for 5 days during activation of HSCs, compared to
cell morphology after expression of full-size TRAM2 and ex-
pression of the control virus, as well as to noninfected HSCs, is
shown in Fig. 4. Green staining of the cells (in the nucleus and
cytoplasm) resulted from expression of GFP, in addition to
TRAM2 and TRAM2C, by the corresponding viruses and
served as a marker of viral infection. Thus, only cells which
received the virus were visualized, and they represented more
than 90% of total cells. Cells expressing TRAM2C were
smaller and rounded (Fig. 4, top left panel) compared to the
typical stellate appearance of cells expressing full-size TRAM2
(top right panel). The latter were similar in morphology to cells
expressing the control virus (bottom left panel) and to cells
cultured without virus (bottom right panel). Therefore, expres-
sion of human TRAM2 did not have a visible effect on rat
HSCs, but TRAM2C drastically changed the morphology of
HSCs.
Next, we measured procollagen protein in HSCs expressing
TRAM2C and full-size TRAM2 and compared it to cells
FIG. 4. Phenotype of rat HSCs expressing C-terminus-truncated TRAM2 (TRAM2C). Rat HSCs were infected at day 2 after isolation with
adenoviruses expressing TRAM2 with deletion of 66 amino acids at the C terminus (top left panel), expressing full-size human TRAM2 (top right
panel), or expressing control virus (CON, bottom left panel). All viruses also expressed GFP as a marker of infection. After an additional 5 days
(7 days after isolation), an image of the cells was taken under UV light so that only cells expressing the viruses were visible. In the bottom right
panel are HSCs cultured without virus for the same time period. This image was taken under visible light.
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expressing the control virus (Fig. 5). Cells expressing
TRAM2C accumulated less pro-1(I) (Fig. 5A, lane 1) com-
pared to cells infected with the control virus (lane 2). Expres-
sion of -smooth muscle actin (-SMA), another marker of
HSC activation, was not affected, suggesting that TRAM2C
acts as an inhibitor of collagen synthesis but not as a general
inhibitor of HSC activation. Expression of GFP was analyzed
as a control for equal viral delivery, and expression of
TRAM2C was confirmed by Western blotting with anti-HA
antibody. Procollagen accumulation in cells expressing full-
length TRAM2 was similar to that in cells expressing the con-
trol virus (Fig. 5B, lanes 1 and 2). We also measured accumu-
lation of procollagen in the cellular medium between days 6
and 7 (Fig. 5C) and found that cells overexpressing TRAM2C
accumulated about 10-fold less collagen in the medium than
control cells during this 24 h. Based on these results, we con-
cluded that expression of C-terminus-deleted TRAM2 severely
impairs the ability of HSCs to accumulate and secrete collagen
type I.
Depletion of ER Ca2 stores by thapsigargin and calmida-
zolium Cl diminishes collagen synthesis. Since the TRAM2
C-terminal domain interacts with the Ca2 pump of the ER,
Serca2b, we wanted to know if collagen synthesis is dependent
on a high Ca2 concentration in the ER. Therefore, we inhib-
ited Serca2b with thapsigargin or calmidazolium Cl. A control
experiment to show that thapsigargin inhibits Serca2b is shown
in Fig. 6A. At 1.5 min after addition of thapsigargin to fibro-
blasts, the cytoplasmic Ca2 concentration increased sharply,
indicating Ca2 release from the ER. A decrease in cytoplas-
mic Ca2 after 4 min was due to Ca2 leakage into Ca2-free
cell medium. Thus, thapsigargin depleted ER Ca2 stores
within minutes. Next, we measured procollagen synthesis by
HSCs after addition of thapsigargin. As shown in Fig. 6B, the
intracellular procollagen level did not change after 2 h (lane 2),
while it decreased after 4 h of thapsigargin treatment (lane 3).
The level of -tubulin remained unchanged (bottom panel).
We also measured the rate of procollagen secretion into cell
medium. For that, we changed the medium just before addi-
tion of thapsigargin, and therefore there was no procollagen in
the medium at time zero (Fig. 6C, lanes 1 and 4). Newly
accumulated procollagen within 4 h was analyzed by Western
blotting (Fig. 6C). Thapsigargin-treated cells did not secrete
procollagen, because we did not detect its appearance in the
medium after 2 h (lane 2) or after 4 h (lane 3). Control cells
showed a continuous increase in extracellular procollagen dur-
ing the same time period (lanes 5 and 6). This result suggests
that type I procollagen secretion into the cellular medium was
affected almost immediately after thapsigargin addition; how-
ever, the intracellular procollagen level decreased only after
several hours (Fig. 6B). We also measured intracellular levels
of another secreted protein, fibronectin. Fibronectin levels
were unaffected by thapsigargin treatment for up to 4 h (Fig.
6D). Thus, the procollagen steady-state level is more sensitive
to Ca2 depletion than the level of fibronectin, suggesting
more subtle regulation. To exclude possible side effects of
thapsigargin, we treated the cells with another Serca2b inhib-
itor, calmidazolium Cl. Again, there was a decrease in the
intracellular procollagen level detected at 4 h after Serca2b
inhibition (Fig. 6E). From these experiments we concluded
that maintaining ER Ca2 concentrations is critical for colla-
gen accumulation and secretion by HSCs.
ER Ca2 is required for collagen protein assembly. To show
that ER Ca2 is necessary for collagen synthesis in other col-
lagen-producing cells and to provide insight into a mechanism
of this effect, we treated rat fibroblasts with thapsigargin. Fig-
ure 7A shows that the intracellular pro-1(I) level was de-
creased after 6 h of thapsigargin treatment (lane 2), it re-
mained low at 12 h, and it returned to 50% of the starting level
by 24 h, indicating partial recovery. During this period of
thapsigargin treatment, the COL1A1 mRNA steady-state level
remained unchanged (Fig. 7B), suggesting that the decreased
procollagen protein level resulted from either increased pro-
tein degradation or decreased mRNA translation. To distin-
guish between these two possibilities, we treated rat fibroblasts
with thapsigargin for 6 h in the presence or absence of the
proteosome inhibitor MG132 (Fig. 7C). Thapsigargin alone
caused a decrease in pro-1(I), as before (lane 2). MG132
alone did not affect the pro-1(I) level (lane 3); however,
MG132 was able to prevent the thapsigargin-induced procol-
lagen decrease (lane 4). To corroborate this finding, we em-
ployed another proteosome inhibitor, lactacystin. Figure 7D
shows that in the presence of lactacystin, thapsigargin was
FIG. 5. TRAM2C overexpression inhibits pro-1(I) in rat HSCs.
(A) Decrease in the cellular level of pro-1(I). Rat HSCs were infected
with adenovirus expressing TRAM2C (lane 1) or control adenovirus
(CON, lane 2) at day 2 after isolation and cultured for an additional 5
days. Western blots with 50 g of cellular proteins were probed under
reducing conditions with antibodies specific for -SMA and pro-1(I).
Probing with anti-HA antibody (HA) was done as a control for
TRAM2C expression, and probing with anti-GFP antibody (GFP)
served as a control for viral infection. (B) TRAM2 overexpression does
not affect the level of pro-1(I) in HSCs. This experiment was per-
formed similar to that shown in panel A, except adenoviruses express-
ing full-size TRAM2 (TRAM2, lane 2) and control virus (CON, lane 1)
were used. Western blotting was done with anticollagen antibody [pro-
1(I)] or anti-HA antibody (HA) to verify TRAM2 expression.
(C) Two samples of cell medium of cells expressing TRAM2C (lanes
1 and 2) or cells expressing control virus (lanes 3 and 4) were analyzed
by Western blotting as described for panel A. Migration of the pro-
1(I) band is indicated.
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unable to induce a decrease in the intracellular procollagen
level (lane 4). Thus, inhibition of protein degradation rescued
the cellular level of procollagen protein, suggesting that Ca2
depletion accelerates intracellular procollagen degradation.
To assess why type I procollagen is susceptible to intracel-
lular degradation in the absence of high ER Ca2 concentra-
tion, we asked if procollagen polypeptides could be folded into
disulfide-bonded multimers when ER Ca2 stores are de-
pleted. We treated cells with thapsigargin and performed
Western blotting under nonreducing conditions. As shown in
Fig. 7E, 6 h after thapsigargin addition the level of disulfide-
bonded high-molecular-weight procollagen (DBC) decreased
dramatically, with faster kinetics and to a greater extent than
the level of monomers [pro-1(I)] (compare lanes 1 and 2).
DBC was almost undetectable 12 h after addition of thapsi-
gargin, but the cells still contained about 30% of the initial
level of monomers (lane 3). Therefore, we concluded that
accumulation of disulfide-bonded intracellular procollagen is
Ca2 dependent and that disruption of formation of S-S-
bonded multimers of pro- chains precedes its accelerated
intracellular degradation.
DISCUSSION
Type I procollagen is a heterotrimeric secreted protein com-
posed of two pro-1(I) polypeptides and one pro-2(I)
polypeptide (29, 54). These polypeptides are cotranslationally
inserted through translocons into the lumen of the ER, where
they undergo posttranslational modifications and folding into a
triple helix. Folding of procollagen type I is facilitated by the
action of molecular chaperones (7, 25, 31, 32, 37). Chaperones
are important in maintaining the balance between the rate of
translation, rate of modifications, and rate of incorporation of
the chains into the triple helix (12, 51). In the human disease
osteogenesis imperfecta, mutations that impair assembly of the
FIG. 6. Inhibition of Serca2b decreases pro-1(I) synthesis.
(A) Thapsigargin depletes Ca2 from the ER. A 200 nM concentration
of thapsigargin was added to rat fibroblasts at time zero, and the
increase in cytoplasmic Ca concentration was monitored by changes
in Fluo-4 fluorescence. Control cells received DMSO. Cells were in-
cubated in Ca2-free medium, which caused a decrease in cytoplasmic
Ca2 at later time points. (B) Thapsigargin decreases the intracellular
level of pro-1(I). Western blotting results with cellular proteins from
HSCs treated with 200 nM thapsigargin (lanes 1 to 3) or treated with
DMSO (lanes 4 and 5) for the indicated time periods are shown. The
blot was probed with anti-pro-1(I) antibody (top panel) and anti--
tubulin antibody (bottom panel). A 50-g aliquot of protein was ana-
lyzed under reducing conditions. (C) Secretion of pro-1(I) into cel-
lular medium of HSCs is blocked by thapsigargin. At time zero cell
medium was changed and thapsigargin was added to the cells (lanes 1
to 3), or DMSO was added (lanes 4 to 5). At the indicated time points,
an aliquot of the medium was collected and analyzed by Western
blotting with pro-1(I)-specific antibody under reducing conditions.
Migration of pro-1(I) is indicated to the left. (D) The fibronectin
level was unaffected by thapsigargin treatment. Cells were treated as
described for panel B, and the cellular level of fibronectin was deter-
mined by Western blotting (upper panel). The same samples were
probed for -tubulin (lower panel), as a control for loading. (E) Cal-
midazolium Cl decreases pro-1(I). The experiment was done as de-
scribed for that in panel B, except calmidazolium Cl was added at 10
M. One additional time point was taken at 6 h. Western blotting was
done with anticollagen antibody [pro-1(I)].
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triple helix result in hypermodified chains (4, 49). Thus, syn-
thesis of type I collagen seems to be a tightly regulated process.
In this paper we provided insight into a role of the TRAM2
protein in collagen synthesis. We have shown that (i) TRAM2
is a homolog of TRAM, which is an integral part of the trans-
locon (28), but it has a unique C terminus; (ii) TRAM2 is
dramatically upregulated during activation of HSCs, a process
associated with increased synthesis of type I collagen; (iii) the
unique C-terminal region of TRAM2 interacts with the Ca2
pump of the ER, Serca2b, and deletion of this region converts
TRAM2 into an inhibitor of procollagen type I synthesis; (iv)
maintaining a high Ca2 concentration in the ER is critical for
folding and secretion of type I procollagen; and (v) unfolded
type I collagen is degraded intracellularly by a proteosome-
mediated mechanism.
When quiescent HSCs are compared to HSCs cultured for 7
days, there is a 50- to 60-fold increase in the steady-state level
of COLL1A1 mRNA (46). Type I procollagen protein cannot
be detected by Western blotting in quiescent HSCs, and its
accumulation starts at day 4 in culture with a steady increase
until day 7 (unpublished results). To sustain such an increase in
procollagen synthesis, HSCs must upregulate components of
the collagen biosynthetic pathway. Molecular chaperones are
necessary for folding of procollagen type I, and it has been
documented that an increase in HSP47, a collagen-specific
molecular chaperone, parallels the increase in collagen synthe-
sis in various tissues (14, 38, 40, 55). The number of translocons
per cell must also increase during activation of HSCs, because
rough ER becomes more prominent during their activation
into myofibroblast-like cells (17, 50). In our microarray study
we detected upregulation of the Sec 10-like 1 gene and Sec 23
homolog B gene, encoding components of the protein secre-
tion pathway. Three Ca2 binding proteins were also upregu-
lated on our microarray: calmodulin, reticulocalbin, and cal-
pain. TRAM is an integral part of translocon, but the function
of this protein is not clear. In vitro reconstitution experiments
have shown that it is required for translocation of some pro-
teins, but not all, across the lipid bilayer (21). One report
suggested that it controls the exposure of nascent ApoB
FIG. 7. Inhibition of Serca2b inhibits disulfide bonding and intra-
cellular degradation of pro-1(I). (A) Thapsigargin causes a transient
decrease in the cellular pro-1(I) steady-state level. Rat fibroblasts
were treated with thapsigargin (lanes 1 to 4) or DMSO (lanes 5 to 7)
for the indicated time periods. Cellular proteins were analyzed by
Western blotting with pro-1(I)-specific antibody under reducing con-
ditions. (B) Thapsigargin does not affect the steady-state level of col-
lagen 1(I) mRNA. From the same cells as used in panel A, total RNA
was extracted and 10 g was analyzed by RNase protection assay with
riboprobe specific to collagen 1(I) mRNA and GAPDH mRNA, as a
control. Migration of the specific protected bands is indicated. (C) The
proteosome inhibitor MG132 blocked the decrease in intracellular
pro-1(I). Fibroblasts were incubated with DMSO (lane 1), with 200
nM thapsigargin (lane 2), with 100 M MG132 (lane 3), or with both
thapsigargin and MG132 (lane 4) for 6 h. Cellular proteins were
extracted and analyzed by Western blotting for pro-1(I) (top panel)
and -tubulin (bottom panel) under reducing conditions. (D) The
proteosome inhibitor lactacystin blocks the thapsigargin-induced de-
crease in intracellular pro-1(I). The experiment was done as de-
scribed for panel C, except that lactacystin was added at 50 M. Only
expression of pro-1(I) is shown. (E) Thapsigargin completely inhibits
formation of disulfide-bonded procollagen. Fibroblasts were incubated
with thapsigargin (lanes 1 to 3) for the indicated time periods. Lane 4
represents control cells incubated with DMSO for 12 h. Cellular pro-
teins were extracted, and 50 g was analyzed by Western blotting
under nonreducing conditions with pro-1(I)-specific antibody. Migra-
tion of high-molecular-weight DBC and pro-1(I) monomers is indi-
cated on the left.
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polypeptide to the cytoplasm during the translocation process
(24). TRAM2 has a high degree of homology to TRAM, except
for the C-terminal domain. TRAM2 is upregulated during
activation of HSCs (Fig. 2), and this parallels the increase in
procollagen synthesis, while TRAM mRNA is not changed in
activation of HSCs. We found that TRAM2 interacts with
pro-1(I) chains, suggesting that it may control their translo-
cation. The unique amino acid sequence of the C-terminal
domain of TRAM2 (Fig. 1) suggests a specific function. We
have described here that this domain interacts with the main
Ca2 pump of the ER, Serca2b (10, 27) (Fig. 3). We favor the
hypothesis that, besides the direct interaction of TRAM2 with
pro-1(I), the interaction between TRAM2 and Serca2b cou-
ples activity of the translocon to the local Ca2 concentration
in the ER. When we overexpressed a truncated version of
TRAM2, it inhibited procollagen type I synthesis and secretion
by HSCs (Fig. 4 and 5). One explanation for this may be that
the truncated TRAM2 displaced the endogenous TRAM2
from the translocons, thus preventing their interaction with
Serca2b. This may lead to disturbed Ca2 homeostasis in the
vicinity of the translocons and inappropriate function of mo-
lecular chaperones. Molecular chaperones require Ca2 for
function, and some are Ca2 binding proteins (2, 15, 34, 35).
Impaired function of molecular chaperones may lead to inef-
ficient folding of the procollagen triple helix, resulting in a
block to secretion and increased intracellular degradation.
Consequently, the change in HSC morphology upon overex-
pression of the truncated form of TRAM2 may be due to the
triggered UPR (22, 41). Even if the UPR had been triggered,
the activation of HSCs was not affected, since expression of
-SMA, as another marker of HSC activation, was unchanged,
suggesting that the cells were differentiating. An alternative
explanation for the inhibitory effect of TRAM2C may be that
the protein disturbs the assembly or geometry of translocons,
rendering them nonfunctional without affecting the function of
molecular chaperones. However, experiments with thapsigar-
gin and calmidazolium Cl suggest that the high Ca2 concen-
tration within the ER is necessary for triple helical procollagen
assembly. Inhibition of triple helical procollagen assembly, as
assessed by high-molecular-weight DBC, is completely abol-
ished by thapsigargin and temporally precedes a decrease in
the steady-state level of pro-1(I) monomers (Fig. 7). Also,
secretion of procollagen into cellular medium ceases almost
immediately after addition of thapsigargin (Fig. 6). This sug-
gests that assembly of procollagen triple helices is Ca2 de-
pendent and is consistent with the hypothesis that one of the
functions of TRAM2 may be to recruit Serca2b to the trans-
locon, which leads to increased local Ca2 concentration and
stimulation of chaperone-mediated folding of triple helical
procollagen. Thus, one of the physiological roles of TRAM2
would be to couple activity of translocon to activation of mo-
lecular chaperones.
TRAM2 is expressed in most cell types (39), where it may
have similar function in folding of proteins other than collagen.
In HSCs and fibroblasts, which secrete primarily collagen type
I, its role may be predominantly in procollagen synthesis, as
suggested by coprecipitation of TRAM2 and pro-1(I). Exis-
tence of yet another homolog of TRAM, the “protein similar
to TRAM” (accession number BC 030831), suggests that there
is a family of TRAM-related proteins with distinct functions in
protein translocation. However, coupling of Serca2b to the
translocon may be the specific function of TRAM2.
The decrease in intracellular pro-1(I) induced by thapsi-
gargin was inhibited by the proteosome inhibitors MG132 and
lactacystin (Fig. 7). This suggests that Ca2 depletion leads to
increased intracellular procollagen degradation. Studies of fi-
broblasts derived from osteogenesis imperfecta patients have
shown that unassembled procollagen polypeptides undergo in-
tracellular degradation by a proteosome-dependent mecha-
nism (18). Our experiments with two different proteosome
inhibitors confirmed that the cytoplasmic proteosome is in-
volved in degradation of unassembled pro- chains. This im-
plies that unassembled pro- chains must be retrotranslocated
into the cytoplasm. How procollagen chains are targeted for
destruction and returned to the cytoplasm is unknown. One
possibility is that the polypeptides remain associated with the
ER membrane until proper modifications are made and until
they initiate productive folding into the triple helix. In such a
case, misfolded or hypermodified chains would be reloaded
into the translocon and reverse translocated into the cytoplasm
for degradation. Elucidation of this mechanism has profound
implications on how the biosynthesis of type I procollagen is
regulated and if it takes place entirely on the membrane of the
ER. Folding of type III procollagen could be achieved when its
C-terminal domain was replaced with a single transmembrane
domain of HA (8). Thus, procollagen folding can take place on
the membrane of the ER. If procollagen synthesis is membrane
bound, this would greatly increase the local concentration of
the components involved. It has been reported that lysyl hy-
droxylase is associated with the membrane of the ER (48), and
our investigators have postulated that COLL1A1 mRNA and
COLL1A2 mRNA may be targeted for coordinated translation
by the conserved 5 stem-loop (44). Elucidation of all compo-
nents of the translocation-synthesis machinery for type I col-
lagen is, therefore, an important future goal.
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